Roberto Sommavilla

Roberto Sommavilla is a Study Clinical Lead (Ph3 and Ph1 studies) in the Global Development Oncology at AstraZeneca since June 2019, focused on breast cancer and haematology. Previously Medical Advisor Haematology at Novartis Pharma Schweiz AG (April 2017- May 2019) leading the myeloproliferative malignancies indications. He has previous long experience as Global Project Leader – Investigator III – Lab Head – Protein Engineering and Ophthalmology at Novartis Institutes for BioMedical Research (NIBR) (March 2011 – April 2017) where he lead project teams and brought into the clinic a number of antibody derivatives. He has experience since Dec 2017 as consultant for antibody preclinical and clinical development in oncology. Previously he was a scientist at Philochem AG (Switzerland; 2006-2010) during his doctoral studies in immunoncology at the Swiss Federal Institute of Technology Zurich, Switzerland, where he learned phage technology, antibody engineering and lead preclinical projects.
Roberto Sommavilla has covered growing responsibilities in both clinical research (clinical lead of Ph3 and Ph1 studies), translational and preclinical research in oncology for almost 15y, enabling the generation of a number of novel agents in the preclinical field and their transition into clinical development. Roberto has also field-experience in the Swiss haematology medical community as Medical Advisor, winning the Europe Novartis Oncology Award for Innovation in 2019.